Friday, January 02, 2015
United Therapeutics Corporation announced today the signing of an agreement with DEKA Research & Development Corp. for the development of a potential technology breakthrough in the subcutaneous delivery of Remodulin® (treprostinil) Injection to patients with pulmonary arterial hypertension (PAH) via a pre-filled semi-disposable pump system.
"The new DEKA semi-disposable pump system will advance the convenience and delivery of subcutaneous Remodulin," said Martine Rothblatt, Ph.D., Chairman and Co-CEO of United Therapeutics. "In addition, it may bring the benefits of parenteral prostacyclin therapy to the thousands of PAH patients who are using the current delivery system or for those patients who no longer receive adequate benefit from oral and inhaled treatments."
"We are pleased to advance the state of technology and engineering in subcutaneous drug delivery systems," said Dean Kamen, President of DEKA. "Our mastery of precision fluid dynamics, coupled with drug pre-filled in special modules, has enabled an unparalleled reduction in pump size for the benefit of patients."
United Therapeutics expects to introduce the new subcutaneous Remodulin delivery system in the 2016-2018 timeframe. Financial terms of the agreement were not announced.
Source : http://www.prnewswire.com/
